Magnesium oxychloride cement (MOC) has the advantage of high early strength. However, it has the defect of poor water resistance. Considering this performance, we use γ-polyglutamic acid (γ-PGA) and chitosan (CS) to modify MOC. The effects of γ-PGA and CS such as strength, in vitro degradation and in vitro bioactivity of MOC were studied. Based on the preparation of γ-PGA and CS modified MOC (γ-PGA/CS-MOC) composite bone cement, the strontium ranelate (SrR) was loaded on. The results showed that the softening coefficient of γ-PGA/3 wt.% CS-MOC after soaking in SBF for 28 d reached 0.48, while that of control group (without CS and γ-PGA) was only 0.35; Cell experiments indicated that SrR could promote differentiation into osteoblasts. After the γ-PGA/CS-MOC composite bone cement containing SrR was implanted into the osteoporotic bone defect for 12 w, it was found that the material was gradually absorbed and the new bone tissue grew. The results showed that SrR/γ-PGA/CS-MOC composite bone cement had a potential application prospect in the repair of osteoporotic bone defects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijbiomac.2024.137426 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Associations between bone material strength index and FRAX scores.
J Bone Miner Metab
January 2025
Deakin University, IMPACT- Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Geelong, Australia.
Introduction: Impact microindentation (IMI) measures bone material strength index (BMSi) in vivo. However, its ability to predict fractures is still uncertain. This study aimed to determine the association between BMSi and 10 year fracture probability, as calculated by the FRAX algorithm.
View Article and Find Full Text PDFCardiovascular safety of osteoanabolic agents.
J Bone Miner Metab
January 2025
Toranomon Hospital Endocrine Center, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-8470, Japan.
Purpose: Several osteoanabolic agents have been developed to build new bone more efficiently than anti-resorptive drugs. Among them, romosozumab, an anti-sclerostin antibody, is a potent pharmacological tool to prevent fractures in osteoporosis patients. The efficacy of romosozumab in preventing osteoporotic fractures is robust.
View Article and Find Full Text PDFRegulation of enzymatic lipid peroxidation in osteoblasts protects against postmenopausal osteoporosis.
Nat Commun
January 2025
State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, 510632, China.
Oxidative stress plays a critical role in postmenopausal osteoporosis, yet its impact on osteoblasts remains underexplored, limiting therapeutic advances. Our study identifies phospholipid peroxidation in osteoblasts as a key feature of postmenopausal osteoporosis. Estrogen regulates the transcription of glutathione peroxidase 4 (GPX4), an enzyme crucial for reducing phospholipid peroxides in osteoblasts.
View Article and Find Full Text PDFOleandrin inhibits osteoclast differentiation by targeting the LRP4/MAPK/NF-κB signalling pathway to treat osteoporosis.
Int Immunopharmacol
January 2025
Department of Orthopedic, Qilu Hospital of Shandong University, Jinan, Shandong 250012, China; Department of Emergency and Critical Care Medicine, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School of Nanjing Medical University, China. Electronic address:
Osteoporosis is a common inflammation-related disease in which the release of proinflammatory cytokines promotes bone loss. Oleandrin is a monomer compound extracted from the leaves of the Nerium oleander plant, has been shown to exert an anti-inflammatory effect on a variety of inflammation-related diseases. However, its role in osteoporosis and the underlying mechanisms remain unclear.
View Article and Find Full Text PDFComparative cardiovascular safety of romosozumab versus bisphosphonates in Japanese patients with osteoporosis: a new-user, active comparator design with instrumental variable analyses.
J Bone Miner Res
January 2025
Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima Medical University, Fukushima-city, Fukushima, Japan.
This study analyzed the association of romosozumab, a human monoclonal antibody with bone-forming and bone resorption-inhibiting effects, and bisphosphonates with the development of cardiovascular disease among patients with osteoporosis. A new-user design was employed to address selection bias, and instrumental variable analysis was used to address confounding by indication. Japanese patients aged ≥40 years, diagnosed with osteoporosis or experienced a fragility fracture, were admitted to medical facilities covered by a commercial administrative claims database, and newly prescribed romosozumab or bisphosphonates after the commercialization of romosozumab in Japan (March 4, 2019) were included based on verification of a 180-day washout period.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!